BACKGROUND
Haemorrhagic complications, including epistaxis, are the main reason for discontinuation of antiplatelet therapy in patients after stent implantation which increases risk of in-stent thrombosis.
AIM
To evaluate the incidence of bleeding complications leading to premature discontinuation of antiplatelet therapy in patients after percutaneous coronary intervention (PCI) with stent im...
